Retatrutide

New Clients

Starting at $380 / month

Retatrutide is a groundbreaking triple agonist that targets glucagon receptors, gastric inhibitory polypeptide, and glucagon-like peptide-1, synergistically enhancing insulin secretion, improving glucose homeostasis, and refining appetite modulation. individuals on retatrutide lost 22% of body weight at 48-weeks of treatment.

beyond glycemic control and weight reduction, retatrutide shows promise in mitigating cardiovascular risk factors and addressing non-alcoholic fatty liver disease, expanding its potential impact on metabolic health.